J & J seeks FDA nod for groundbreaking UC therapy
Johnson & Johnson has submitted an FDA application for the first subcutaneous IL-23 inhibitor for ulcerative colitis. This drug could offer patients a groundbreaking at-home treatment option.
FDA
FDA proposes ending use of decongestant found in many cold, allergy medicines
Currently, oral phenylephrine is widely used as a nasal decongestant active ingredient in many O-T-C monograph drug products.